An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

Crinetics Pharmaceuticals, Inc. is developing an oral nonpeptide drug for acromegaly patients. The drug is claimed to have advantages over injectable and oral somatostatin analogues. A phase 3 trial ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

Crinetics Pharmaceuticals announced that it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, highlighting the investigational treatment ...

Crinetics Pharmaceuticals' oral med paltusotine regulated levels of a hormone associated with the pituitary gland disorder acromegaly in a phase 3 test, setting up a regulatory submission for the ...

Levels of the hormone increase with disease severity, a new study has found. Plasma levels of insulin-like growth factor 1 (IGF-1) could give clinicians a better understanding of whether a patient ...